By: B. De Laere , M. Mayrhofer , T. Whitington , P-J. Van Dam , P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, W. Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , N. Beije , I. De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , L. Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , J. Del-Favero , S. Sleijfer , A. Uhlen , J. Yachnin , S. Van Laere PhD, H. Grönberg , J. Lindberg , L. Dirix MD, PhD
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)